Partnership / Collaboration · Africa · Announced 27 Aug 2026
CEPI → Minapharm
Partnership / Collaboration deal between CEPI (Norway) and Minapharm (Egypt), announced 27 Aug 2026. Value: $16.5m.
Parties: CEPI (Coalition for Epidemic Preparedness Innovations) (Norway) → Minapharm Group (Egypt)
- Deal type
- Partnership / Collaboration
- Value
- $16.5m
- Territory
- Africa (Phase 1 in Africa; DRC outbreak; local manufacturing in Egypt)
- Therapeutic area
- Vaccines
- Asset
- Bundibugyo ebolavirus vaccine candidate, MVA-CR19 recombinant MVA platform
- Announced
- 27 Aug 2026
Our analysis
Executive summary.
CEPI will award up to US$16.5 million to Minapharm Group to advance its Bundibugyo ebolavirus vaccine candidate — designed by Minapharm's Berlin subsidiary ProBioGen on its proprietary MVA-CR19 platform — through preclinical development into a Phase 1 trial in Africa.
The full analysis is free to read with a work email on this page.
Source: PR Newswire